U.S.-based Biomarin Pharmaceutical Inc.’s treatment for one of the most common forms of dwarfism received clearance from the European Commission, becoming the first therapy to get an approval in the region for achondroplasia.

The chief executive officer, Edward Kaye, of Cambridge, Mass.-based Sarepta Therapeutics (SRPT) recently indicated the company is looking to acquire a drug to treat Duchenne muscular dystrophy (DMD).   On June 29, 2015, Sarepta announced it had completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) […]

One U.S. biotech company is celebrating Independence Day weekend with a fresh $1 billion in cash from a corporate partner, which it was able to secure without giving up its corporate independence. For more, read on: Juno Secures $1B in Cancer Deal With Celgene Seattle-based Juno Therapeutics was the talk of the industry this week. […]